2023 World Conference on Lung Cancer (Posters)-EP03.06. The Landscape of NF1 Alteration in Chinese Non-Small-Cell Lung Cancer Patients

EP03.06. The Landscape of NF1 Alteration in Chinese Non-Small-Cell Lung Cancer Patients - PDF(Abstract)

Pdf Summary

This study examines the landscape of NF1 alteration in Chinese patients with non-small-cell lung cancer (NSCLC). NF1 is a tumor suppressor gene that regulates Ras signaling. The researchers analyzed 1331 normal-paired samples from lung cancer patients using next-generation sequencing. They found that the NF1 gene was altered in 5.1% of all NSCLC samples. Patients with NF1 mutations were more likely to be elderly and male compared to those without NF1 mutations. Various types of NF1 mutations were identified, including missense, nonsense, frameshift, splice site, copy number loss, and deletion mutations. Furthermore, NF1 mutation carriers also had other actionable or driver mutations, with the most frequent ones being TP53, EGFR, LRP1B, PTPRD, and CDKN2A. In patients with NF1/EGFR co-mutations, the EGFR mutation rate was lower compared to those with single EGFR mutations. In a larger cohort that included samples from 32 studies, NF1/EGFR co-mutation patients had longer overall survival compared to patients with single NF1 or EGFR mutations. The researchers conclude that NF1 genetic alterations are critical for prognosis and identifying therapeutic targets in NSCLC. They also highlight the enrichment of TP53 mutations in NF1 mutant patients and the potential for NF1/EGFR co-mutation as a favorable prognostic marker. Overall, this study provides insights into the genomic landscape of NF1 alteration and its implications for NSCLC patients.

Asset Subtitle

Zhenliang Shi

Meta Tag

Speaker Zhenliang Shi

Topic Tumor Biology: Translational Biology - Translational Therapeutics

Keywords

NF1 alteration

Chinese patients

NSCLC

tumor suppressor gene

next-generation sequencing

NF1 mutations

elderly

missense mutations

TP53 mutations

EGFR mutations